Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010029174) METHOD FOR CLASSIFYING A CANCER PATIENT AS RESPONDER OR NON-RESPONDER TO IMMUNOTHERAPY
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. A method of classifying a patient as a responder or non-responder comprising the steps of: (a) determining the expression levels of one or more genes in a patient-derived sample, wherein the gene(s) are selected from Table 1 ;

(b) classifying the patient to either a responder or non-responder group based on the expression levels of (a).

2. A method of characterising a patient as a responder or non-responder to therapy comprising the steps:

(a) analysing a patient derived sample for differential expression of the gene products of one or more genes of Table 1 , and

(b) characterising the patient from which the sample was derived as a responder or non- responder, based on the results of step (a), wherein the characterisation step is optionally performed by reference or comparison to a standard.

3. A method according to claim 2, in which the standard is a patient-derived sample from a patient having a known clinical outcome.

4. A method according to claim 1 or 2, in which the one or more genes of Table 1 are at least 5, at least 10, at least 15, at least 20 and/or all the genes listed in Table 1 and/or any combination thereof.

5. A method according to claim 1 or 2, in which the one or more genes of Table 7 are 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32 or all of the genes of Table 1 and/or any combination thereof.

6. A method according to any of claims 1 to 5, in which at least one gene product is upregulated.

7. A method according to any of claims 1 to 6, in which at least 80% of the gene products are upregulated.

8. A method according to any of claims 1 to 7, further comprising the step of determining whether the gene products are upregulated and/or downregulated as shown in Table 5.

9. A method according to claim 8, wherein a determination that the gene products are upregulated and/or downregulated as shown in Table 5 indicates a responder.

10. A method as defined in any of claims 1 to 9 comprising the further step of identifying a patient as a responder, and selecting the patient for therapy.

11. A method according to any of claims 1 to 10 in which genes are immune related genes.

12. A method according to any of claims 1 to 11 , in which the differential expression, comparison or classifying step is performed using an algorithm.

13. A method according to any preceding claim comprising use of a probe for the identification of the one or more gene products.

14. A method according to any preceding claim comprising use of a microarray kit.

15. A microarray comprising one or more polynucleotide probes complementary and hybridisable to a sequence of the gene product of at least one gene or immune mediated gene selected from the genes listed in Table 1 , in which polynucleotide probes or probe sets complementary and hybridisable to the genes or immune mediated genes constitute at least 50% of the probes or probe sets on said microarray.

16. A microarray comprising one or more polynucleotide probes complementary and hybridisable to a sequence of the genes or immune mediated genes of Table 1 , or a microarray in which polynucleotide probes or probe sets complementary and hybridisable to the genes or immune mediated genes of Table 1 constitute at least 50% of the probes or probe sets on said microarray.

17. A diagnostic kit comprising at least one component for performing the method of any one of claims 1 to 16.

18. A method of treating a patient characterised as a responder according to the method of claims 1 to 14 or use of the microarray of claims 15 to 16 or the diagnostic kit of claim 17, comprising administering a composition comprising a tumour associated antigen to the patient.

19. Use of a composition comprising a tumour associated antigen in the preparation of a medicament for the treatment of patients determined to have or characterised as a responder according to the method of claims 1 to 14 or use of the microarray of claims

15 to 16 or the diagnostic kit of claim 17.

20. A method or use according to claims 18 or 19, in which the tumour associated antigen is a MAGE antigen.

21. A method or use according to claims 18 to 20, in which the composition further comprises an adjuvant.